Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SESC 01 in Tinea Pedis
NCT03135912Phase 2Completed
- Sponsor
- South End Skin Care
- Start
- Jan 2017
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SESC-01 in tinea pedis (3 arms), sponsored by South End Skin Care. Primary endpoint: Effective Treatment Rate (Mycological Cure and Minimal Symptoms) at 6 weeks. Started Jan 2017; status: completed.
02
Drugs
SESC-01
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT03135912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135912.